⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Long-term Effectiveness of Cannabidiol (CBD) Against Focal Seizures in Tuberous Sclerosis Complex (TSC): Results from the GWPCARE6 Open-label Extension (OLE) Trial (P8-1.001)

Joyce Y. Wu E. Martina Bebin Teresa Greco Kelly Simontacchi

View Full Paper

Ask AI

Bookmark

Share

Abstract

Post hoc analysis to evaluate CBD effectiveness against focal seizure subtypes (focal aware seizures [FAS], focal impaired awareness seizures [FIAS], and focal to bilateral tonic-clonic seizures [FBTCS]) in the GWPCARE6 OLE.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wu et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db6435876781a9 https://doi.org/10.1212/wnl.0000000000206411

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program2024 · 9 citations
2Caregiver-reported Seizure Outcomes with Real-world Use of Cannabidiol (CBD) in Tuberous Sclerosis Complex (TSC): Interim Results From the BECOME-TSC Survey (P8-1.005)2024
3Caregiver-reported Nonseizure Outcomes with Real-world Use of Cannabidiol (CBD) in Tuberous Sclerosis Complex (TSC): Interim Results from the BECOME-TSC Survey (P8-1.010)2024
4Long-term Effectiveness of Cannabidiol (CBD) Against Focal-onset Seizures in Treatment-resistant Epilepsies (TRE): Experience from the Expanded Access Program (EAP) (S29.005)2024
5Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorders (TAND) Outcomes Following Adjunctive Cannabidiol (CBD) Treatment: 6-Month Intermediate Analysis of the EpiCom Trial (S5.005)Human Clinical Trial · 2026